EU delays approval of Novavax’s revised Covid jab

Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. EU regulators have delayed a decision to approve Novavax’s variant-tailored Covid-19 vaccine, in a setback for the US-listed biotech which is battling a slump in demand for coronavirus jabs. The European Medicines Agency, which was…

Read More

BioNTech: Not Just Another Jab In The Arm (NASDAQ:BNTX)

PeopleImages/iStock via Getty Images Introduction Founded in 2008, BioNTech (NASDAQ:BNTX) is a global immunotherapy leader, pioneering mRNA vaccines, gene therapies, and targeted antibodies. Their portfolio includes the COVID-19 vaccine Comirnaty and numerous research initiatives. Their growth in 2022 solidified their leading role in modern therapies. In my previous analysis, I highlighted that BioNTech, despite declining…

Read More